Poolbeg Pharma Dosed First Eight Trial Participants
The clinical trial evaluates POLB 001 for preventing Cytokine Release Syndrome in myeloma patients receiving teclistamab.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Do you trust that current pharmaceutical clinical trial processes adequately prioritize patient safety?
Poolbeg Pharma has dosed eight participants in its ongoing clinical trial for POLB 001. The trial aims to assess the candidate as a preventative therapy for Cytokine Release Syndrome in patients treated with the bispecific antibody teclistamab.
Why it matters
This trial addresses the severe inflammatory response often triggered by cancer immunotherapies like teclistamab. The results will establish whether POLB 001 can mitigate this complication without compromising the effectiveness of the underlying cancer treatment.
The clinical study is currently dosing patients from a targeted group of 30, following an initial six-patient safety cohort. Researchers are evaluating the drug's performance against the incidence of Cytokine Release Syndrome, a condition where immune cells release excessive inflammatory cytokines into the blood.
The players
Poolbeg Pharma
A biopharmaceutical company focused on developing therapies for infectious and inflammatory diseases.
The details
The trial centers on POLB 001, a candidate being tested to prevent Cytokine Release Syndrome in patients receiving teclistamab, a bispecific antibody that redirects T-cells to kill cancer cells. The recruitment process requires coordination across multiple clinical sites to monitor safety in the early cohort before expanding to the full target group. The study specifically targets patients with multiple myeloma, a cancer that forms in plasma cells, who are susceptible to immune-driven inflammatory responses during immunotherapy.
Timeline
July 2026: The first patient was dosed in the clinical trial.
September 28, 2026: Poolbeg Pharma provided a formal update on trial recruitment.
The Tech Race
The trial sits within a crowded field of clinical efforts to manage the toxicity associated with bispecific antibody therapies. Researchers are working to ensure that supportive care options can keep pace with the increasing adoption of these potent cancer treatments.
This study marks the ongoing recruitment phase for a trial that may eventually provide a new standard of care for multiple myeloma patients. There is no current impact for patients as the drug remains in clinical testing, with site expansions expected in the coming months.
The takeaway
The clinical community is tracking this trial to determine if prophylactic treatment can safely permit broader use of powerful immunotherapies. Watch for future updates on trial site expansion as the company moves toward its goal of 30 total participants.
Further reading
For more on the current landscape of therapeutic research, visit Biotech.
Live Poll
Do you trust that current pharmaceutical clinical trial processes adequately prioritize patient safety?
